Nov 17, 2022 / 01:00PM GMT
Presentation
Nov 17, 2022 / 01:00PM GMT
=====================
Corporate Participants
=====================
* Baisong Mei
Editas Medicine, Inc. - Senior VP & Chief Medical Officer
* Gilmore OâNeill
Editas Medicine, Inc. - President & CEO
* Ron Moldaver
Editas Medicine, Inc. - IR
=====================
Conference Call Participants
=====================
* Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst
* Jay Olson
Oppenheimer & Co. Inc., Research Division - Executive Director & Senior Analyst
* Joel Lawrence Beatty
Robert W. Baird & Co. Incorporated, Research Division - Senior Research Analyst
* Liisa Ann Bayko
Evercore ISI Institutional Equities, Research Division - MD & Fundamental Research Analyst
* Lisa A. Walter
RBC Capital Markets, Research Division - Senior Associate
* Mani Foroohar
SVB Securities LLC, Research Division - Senior MD of Genetic Medicines and Senior Research Analyst
* Matthew
Editas Medicine Inc
(NAS:EDIT)
$
3.74
-0.03 (-0.79%)
Market Cap: 308.46 Mil
Enterprise Value: 71.35 Mil
PE Ratio: 0
PB Ratio: 1.34
GF Score: 51/100 Editas Medicine Inc Announces EDIT-101 Clinical Update Presentation Transcript
Nov 17, 2022 / 01:00PM GMT
Release Date Price:
$11.01
(-10.12%)
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot